Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs NOV Inc. Common Stock (NOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs NOV Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.34 (market cap $12.58B), while NOV Inc. Common Stock trades at $18.99 (market cap $6.77B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and NOV Inc. Common Stock pays a 1.9% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and NOV Inc. Common Stock for 1 Days on average.
| HALO | NOV | |
|---|---|---|
Market Cap | $12.58B | $6.77B |
Volume | 2,179,278 | 3,592,724 |
Sector | Health | Energy |
52-Week High | $115.22 | $21.71 |
52-Week Low | $61.63 | $12.31 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $7.93B |
Dividend Yield | — | 1.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About NOV Inc. Common Stock
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →
